Ruxolitinib (INCB018424) is a Selective JAK1/2 Inhibitor for Cancer Research
JAK (Janus kinase) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Particularly, JAK2 is a member of the JAK family of cytoplasmic…